Abstract : Background: RAS mutations have been shown to confer resistance to anti-EGFR treatment. We assessed here the results of the PETACC8 trial (Cetuximab + FOLFOX vs FOLFOX) in full wild type (WT) patients (pts) (RAS & BRAF). The prognostic impact of individual rare RAS and BRAF mutations has been tested.
Methods: Exons 2, 3 and 4 of KRAS and NRAS as well as BRAF exon 11 and 15 have been sequenced, using the ampliseq colon lung cancer panel V2, among the pts who have signed informed consent for translational research. The impact of cetuximab on Time To Recurrence (TTR), Disease Free Survival (DFS) and Overall Survival (OS), has been investigated in pts RAS WT, RAS & BRAF double WT tumors and in pts with rare...
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01494512
Contributeur : Lnc - Université de Bourgogne
<>
Soumis le : jeudi 23 mars 2017 - 15:48:48
Dernière modification le : mardi 13 août 2019 - 11:06:19
J. Taieb, K. Le Malicot, R. Balogoum, J. Tabernero, E. Mini, et al.. Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial. 41st ESMO Congress (ESMO 2016), Oct 2016, Copenhague, Denmark. pp.4610, ⟨10.1093/annonc/mdw370.10⟩. ⟨hal-01494512⟩
